Pharmaron Acquires 82.54% of Biortus Biosciences

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Pharmaron Acquires Absorption Systems

November 9, 2020

Healthcare Services

Pharmaron Beijing Co., Limited acquired 100% of Absorption Systems for up to US$137.5 million in cash. The purchase brings Absorption Systems’ non-clinical DMPK/ADME and bioanalysis capabilities and U.S. lab footprint (Philadelphia, San Diego and Boston) into Pharmaron’s integrated drug R&D services platform to expand capabilities and U.S. presence.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.

Ligand Pharmaceuticals to Acquire APEIRON Biologics AG for $100 Million

July 8, 2024

Healthcare Services

Ligand Pharmaceuticals entered into a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash, with additional contingent consideration of up to $28 million tied to future QARZIBA commercial and regulatory milestones. The acquisition grants Ligand royalty rights to QARZIBA (dinutuximab beta), an oncology immunotherapy for high-risk neuroblastoma marketed in 35+ countries.